Citation(s)
- Engler B, Freiman I, Urbanski M, Szabo B
Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. J Pharmacol Exp Ther. 2006 Feb;316(2):608-17. Epub 2005 Oct 7.
- Fox SH, Henry B, Hill M, Crossman A, Brotchie J
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2002 Nov;17(6):1180-7.
- Ha AD, Jankovic J
Pain in Parkinson's disease. Mov Disord. 2012 Apr;27(4):485-91. doi: 10.1002/mds.23959. Epub 2011 Sep 23. Review.
- Kluger B, Triolo P, Jones W, Jankovic J
The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015 Mar;30(3):313-27. doi: 10.1002/mds.26142. Epub 2015 Feb 4. Review.
- Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.
- Lynch ME, Ware MA
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. J Neuroimmune Pharmacol. 2015 Jun;10(2):293-301. doi: 10.1007/s11481-015-9600-6. Epub 2015 Mar 22. Review.
- More SV, Choi DK
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol Neurodegener. 2015 Apr 8;10:17. doi: 10.1186/s13024-015-0012-0. Review.
- Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O; DoPaMiP Study Group
Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008 Jul 30;23(10):1361-9. doi: 10.1002/mds.22142.
A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease
Details for clinical trial NCT03639064
